Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a **multi-electrolyte peritoneal dialysis solution** composed of sodium chloride, calcium chloride, magnesium chloride, dextrose monohydrate, and an additional sodium-containing buffer component, most plausibly **sodium lactate** based on approved U.S. product labels for closely matching formulations such as DIANEAL. These solutions are pharmacologically inactive replacement/dialysis fluids rather than receptor-targeted drugs: dextrose creates an osmotic gradient across the peritoneal membrane to drive ultrafiltration, while the electrolyte and buffer components help correct fluid, electrolyte, and acid-base abnormalities during peritoneal dialysis. The formulation class is used for the management of **acute renal failure**, **chronic renal failure**, and **chronic kidney failure** via **intraperitoneal** administration. Because the input name omits the exact sodium salt/buffer and does not uniquely map to a single branded product, it is best treated as a nonspecific formulation-level description rather than one uniquely identifiable commercial drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + calcium chloride + magnesium chloride + dextrose monohydrate + sodium.